

Jude M Phillip

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3831956/publications.pdf>

Version: 2024-02-01

38
papers

1,766
citations

331670

21
h-index

361022

35
g-index

41
all docs

41
docs citations

41
times ranked

3654
citing authors

#	ARTICLE	IF	CITATIONS
1	Histamine H4 Receptor Agonism Induces Antitumor Effects in Human T-Cell Lymphoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1378.	4.1	5
2	Deep learning identification of stiffness markers in breast cancer. <i>Biomaterials</i> , 2022, 285, 121540.	11.4	8
3	Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL. <i>Blood</i> , 2021, 137, 788-800.	1.4	22
4	Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture. <i>Nature</i> , 2021, 589, 299-305.	27.8	155
5	A robust unsupervised machine-learning method to quantify the morphological heterogeneity of cells and nuclei. <i>Nature Protocols</i> , 2021, 16, 754-774.	12.0	58
6	Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures. <i>Cancer Discovery</i> , 2021, 11, 1468-1489.	9.4	119
7	Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas. <i>Cancer Research</i> , 2021, 81, 5202-5216.	0.9	14
8	Fractional re-distribution among cell motility states during ageing. <i>Communications Biology</i> , 2021, 4, 81.	4.4	9
9	Use of the p-values as a size-dependent function to address practical differences when analyzing large datasets. <i>Scientific Reports</i> , 2021, 11, 20942.	3.3	35
10	A Predictive Endothelial-Leukemia Pre-Clinical Platform to Uncover Drug Vulnerabilities for Personalized Treatments. <i>Blood</i> , 2021, 138, 704-704.	1.4	0
11	Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response. <i>Cancer Cell</i> , 2020, 37, 655-673.e11.	16.8	93
12	Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy. <i>Blood</i> , 2020, 135, 1870-1881.	1.4	39
13	A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries. <i>Cancers</i> , 2020, 12, 1603.	3.7	11
14	TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate. <i>Cell</i> , 2020, 182, 297-316.e27.	28.9	63
15	Single-cell morphology encodes metastatic potential. <i>Science Advances</i> , 2020, 6, eaaw6938.	10.3	112
16	Targeting metastasis through the inhibition of interleukin 6 and 8. <i>Breast Cancer Management</i> , 2019, 8, BMT20.	0.2	6
17	BCL6 Evolved to Enable Stress Tolerance in Vertebrates and Is Broadly Required by Cancer Cells to Adapt to Stress. <i>Cancer Discovery</i> , 2019, 9, 662-679.	9.4	31
18	Microenvironmental Signatures Reveal Biological Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) Distinct from Tumor Cell Molecular Profiling. <i>Blood</i> , 2019, 134, 656-656.	1.4	6

#	ARTICLE	IF	CITATIONS
19	EZH2 Gain-of-Function Mutations Generate a Lymphoma-Permissive Immune Niche. <i>Blood</i> , 2019, 134, 2768-2768.	1.4	3
20	Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway. <i>EBioMedicine</i> , 2018, 28, 80-89.	6.1	25
21	Inhibition of ovarian tumor cell invasiveness by targeting SYK in the tyrosine kinase signaling pathway. <i>Oncogene</i> , 2018, 37, 3778-3789.	5.9	22
22	Germline Lysine-Specific Demethylase 1 (<i>LSD1/KDM1A</i>) Mutations Confer Susceptibility to Multiple Myeloma. <i>Cancer Research</i> , 2018, 78, 2747-2759.	0.9	56
23	EB1 and cytoplasmic dynein mediate protrusion dynamics for efficient 3-dimensional cell migration. <i>FASEB Journal</i> , 2018, 32, 1207-1221.	0.5	26
24	It's a numbers game—density-dependent MMP activity mediates cancer cell migration. <i>Oncotarget</i> , 2018, 9, 33867-33868.	1.8	1
25	Heat Shock Factor 1 Reprograms the DLBCL Microenvironment to Evade Immune Surveillance and Support Tumor Growth. <i>Blood</i> , 2018, 132, 2854-2854.	1.4	0
26	THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. <i>Nature Communications</i> , 2017, 8, 14290.	12.8	74
27	Biophysical and biomolecular determination of cellular age in humans. <i>Nature Biomedical Engineering</i> , 2017, 1, .	22.5	74
28	Loss of giant obscurins alters breast epithelial cell mechanosensing of matrix stiffness. <i>Oncotarget</i> , 2017, 8, 54004-54020.	1.8	21
29	Inhibition of the Integrin $\alpha 2 \beta 3$ Improves the Immune and Anti-Lymphoma Effects of Bexarotene in Cutaneous T-Cell Lymphoma (CTCL). <i>Blood</i> , 2017, 130, 732-732.	1.4	24
30	HSP90 Facilitates Oncogene-Induced Metabolic Reprogramming in B-Cell Lymphomas. <i>Blood</i> , 2017, 130, 645-645.	1.4	0
31	Evolution of cellular morpho-phenotypes in cancer metastasis. <i>Scientific Reports</i> , 2016, 5, 18437.	3.3	81
32	The Pro-Tumorigenic Vascular Niche Sustains the T-Cell Acute Lymphoblastic Leukemia Phenotype and Fosters Resistance to Therapy. <i>Blood</i> , 2016, 128, 279-279.	1.4	0
33	The Mechanobiology of Aging. <i>Annual Review of Biomedical Engineering</i> , 2015, 17, 113-141.	12.3	216
34	Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules. <i>Cancer Cell</i> , 2015, 28, 82-96.	16.8	125
35	Volume regulation and shape bifurcation in the cell nucleus. <i>Journal of Cell Science</i> , 2015, 128, 3375-85.	2.0	104
36	Morphological Effects on Expression of Growth Differentiation Factor 15 (GDF15), a Marker of Metastasis. <i>Journal of Cellular Physiology</i> , 2014, 229, 362-373.	4.1	30

#	ARTICLE	IF	CITATIONS
37	Functional interplay between the cell cycle and cell phenotypes. Integrative Biology (United Kingdom), 2013, 5, 523-534.	1.3	23
38	Modulation of keratocyte phenotype by collagen fibril nanoarchitecture in membranes for corneal repair. Biomaterials, 2013, 34, 9365-9372.	11.4	39